Home Amines 936563-96-1
936563-96-1,MFCD20261150
Catalog No.:AA0035Z8

936563-96-1 | 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

Pack Size
Purity
Availability
Price(USD)
Quantity
  
10mg
98%
in stock  
$7.00   $5.00
- +
100mg
98%
in stock  
$12.00   $8.00
- +
250mg
98%
in stock  
$14.00   $10.00
- +
1g
98%
in stock  
$53.00   $37.00
- +
5g
98%
in stock  
$187.00   $131.00
- +
10g
98%
in stock  
$349.00   $245.00
- +
100g
98%
in stock  
$3,070.00   $2,149.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA0035Z8
Chemical Name:
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
CAS Number:
936563-96-1
Molecular Formula:
C25H24N6O2
Molecular Weight:
440.4971
MDL Number:
MFCD20261150
SMILES:
C=CC(=O)N1CCC[C@H](C1)n1nc(c2c1ncnc2N)c1ccc(cc1)Oc1ccccc1
Properties
Properties
 
Form:
Solid  
MP:
153-158°C  
Storage:
Light sensitive;Inert atmosphere;2-8℃;  

Computed Properties
 
Complexity:
678  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
1  
Rotatable Bond Count:
5  
XLogP3:
3.6  

Downstream Synthesis Route
1022150-12-4    814-68-6   
ibrutinib 

[1]Patent:CN107353291,2017,A.Locationinpatent:Paragraph0068;0069;0070

[2]Patent:US2018/44339,2018,A1.Locationinpatent:Paragraph0113;0114

[3]Patent:CN108623606,2018,A.Locationinpatent:Paragraph0048

[4]Patent:US2017/145017,2017,A1.Locationinpatent:Paragraph0127;0128;0133

[5]Patent:CN106188062,2016,A.Locationinpatent:Paragraph0088;0089;0090;0091;0092;0093

[6]Patent:CN108623602,2018,A.Locationinpatent:Paragraph0022;0023;0025

[7]Patent:CN107383017,2017,A.Locationinpatent:Paragraph0016;0038;0039;0040;00410042;0043

[8]JournalofMedicinalChemistry,2015,vol.58,p.9625-9638

[9]Patent:WO2014/176348,2014,A1.Locationinpatent:Page/Pagecolumn66;67

[10]OrganicandBiomolecularChemistry,2015,vol.13,p.5147-5157

[11]Patent:CN105622613,2016,A.Locationinpatent:Paragraph0109;0208;0209;0210;0211;0212;0213-0218

[12]Patent:WO2017/137446,2017,A1.Locationinpatent:Page/Pagecolumn16

[13]Patent:WO2017/163257,2017,A1.Locationinpatent:Page/Pagecolumn19

[14]Patent:CN107286163,2017,A.Locationinpatent:Paragraph0120;0121

[1]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2016/50422,2016,A1Locationinpatent:Page/Pagecolumn13-14

[1]CurrentPatentAssignee:ADVENTINTERNATIONALCORPORATION-WO2016/127960,2016,A1Locationinpatent:Page/Pagecolumn7

[2]CurrentPatentAssignee:TEVAPHARMACEUTICALINDUSTRIESLTD.-WO2016/50422,2016,A1Locationinpatent:Page/Pagecolumn16

[1]CurrentPatentAssignee:SINOBIOPHARMACEUTICALLIMITED;SHANGHAIDUDEMEDICALSCIENCEANDTECHNOLOGYCOLTD-US2018/44339,2018,A1Locationinpatent:Paragraph0091;0092

[2]CurrentPatentAssignee:SUNPHARMACEUTICALINDUSTRIESLIMITED-WO2016/79693,2016,A1Locationinpatent:Page/Pagecolumn29

1022150-12-4    79-10-7   
ibrutinib 

[1]Patent:CN105859728,2016,A.Locationinpatent:Paragraph0056;0057;0058;0068;0069

[2]Patent:CN104557945,2017,B.Locationinpatent:Paragraph0077;0079;0081;0082;0083;0084;0085;0086

[3]Patent:CN107641123,2018,A.Locationinpatent:Paragraph0014;0020

[4]Patent:WO2017/134588,2017,A1.Locationinpatent:Page/Pagecolumn17

Literature

Title: Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

Journal: Toxicology letters 20180701

Title: Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.

Journal: Journal of cancer research and clinical oncology 20180401

Title: Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).

Journal: Expert opinion on investigational drugs 20180101

Title: The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.

Journal: The Journal of biological chemistry 20161014

Title: Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.

Journal: Oncotarget 20160906

Title: Mantle Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20160410

Title: Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine 20160128

Title: Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.

Journal: Chemical research in toxicology 20160119

Title: Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.

Journal: Leukemia 20160101

Title: Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Journal: Blood 20150924

Title: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.

Journal: Drugs 20150501

Title: Ibrutinib in pretreated Waldenström's macroglobulinaemia.

Journal: The Lancet. Oncology 20150501

Title: Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.

Journal: Leukemia 20150401

Title: Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.

Journal: Drug metabolism and disposition: the biological fate of chemicals 20150201

Title: Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.

Journal: Proceedings of the National Academy of Sciences of the United States of America 20140805

Title: Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Journal: Journal of medicinal chemistry 20140626

Title: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).

Journal: Leukemia & lymphoma 20131101

Title: Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma 20130801

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Journal: The New England journal of medicine 20130704

Title: Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

Journal: Expert review of clinical immunology 20130601

Title: Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.

Journal: Current hematologic malignancy reports 20130301

Title: Ibrutinib and novel BTK inhibitors in clinical development.

Journal: Journal of hematology & oncology 20130101

Title: Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.

Journal: Cancer journal (Sudbury, Mass.) 20120901

Title: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Journal: Blood 20120830

Title: Irreversible protein kinase inhibitors: balancing the benefits and risks.

Journal: Journal of medicinal chemistry 20120726

Title: Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

Journal: Cancer cell 20120612

Title: Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.

Journal: Journal of medicinal chemistry 20120524

Title: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Journal: Blood 20120315

Title: Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia.

Journal: Current hematologic malignancy reports 20120301

Title: Novel targeted therapies for mantle cell lymphoma.

Journal: Oncotarget 20120201

Title: Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.

Journal: Bioorganic & medicinal chemistry letters 20111101

Title: Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.

Journal: Neoplasia (New York, N.Y.) 20111101

Title: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Journal: Blood 20110609

Title: Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

Journal: International immunopharmacology 20110401

Title: The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Journal: Arthritis research & therapy 20110101

Title: More than just B-cell inhibition.

Journal: Arthritis research & therapy 20110101

Title: Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Journal: ChemMedChem 20070101

Title: Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.

Title: Herman SE, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011 Jun 9;117(23):6287-96.

Title: Chang BY, et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011 Jul 13;13(4):R115.

Title: Sun Y, et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 2018 Jul;28(7):779-781.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Tags:936563-96-1 Molecular Formula|936563-96-1 MDL|936563-96-1 SMILES|936563-96-1 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one